Heterocyclic Compound Active Ingredients TRIZ Cases
- PI3K and Src Inhibitor Combination for Pancreatic Cancer
Merges PI3K and Src inhibitors to target hyperactivated signaling pathways, improving survival rates despite late detection challenges.
- VDR Ligand and PARP Inhibitor Combination for Chemoresistant Cancer
Inhibiting the vitamin D receptor disrupts homologous recombination DNA repair, enabling PARP inhibitors to overcome chemoresistance in pancreatic cancer.
- NMDA Receptor Antagonist Compositions for Catatonia Treatment
Combining ketamine with antipsychotics overcomes treatment resistance and improves cognitive function in schizophrenia patients.
- Multi-Component Injectable Pain Composition
A multi-component injectable pharmaceutical composition combines analgesic and muscle relaxant agents to address severe chronic pain.
- Allosteric HIV-1 Integrase Inhibitors Overcoming Drug Resistance
Allosteric inhibitors disrupt HIV-1 integrase multimerization, bypassing active-site resistance mechanisms.
- Rho Kinase Inhibitors for Cerebral Aneurysm Treatment
Oral Rho kinase inhibitors stabilize endothelial barriers to prevent vascular leakage, addressing surgical risks in cerebral aneurysm treatment.
- Herbacetin ODC Inhibition Reduces Toxicity
Herbacetin targets specific allosteric sites on ornithine decarboxylase, reducing toxicity compared to DFMO while inhibiting enzyme activity.
- Phenylbiguanide Derivative Modulating T Cell Activity
A phenylbiguanide derivative composition inhibits memory T cell differentiation and promotes effector T cell proliferation to modulate immune responses.
- Nitroxide Antioxidant Modulation of UCP2 Gene Expression
Nitroxide antioxidants decrease UCP2 overexpression to correct irregular gene patterns without complex genetic therapy systems.
- D-Cycloserine and Psychedelic Tryptamine Combination for Neural Pathway Modification
Combining sub-hallucinogenic psychedelic tryptamines with D-cycloserine modifies neural pathways to promote neuroplasticity.
- PDE5 Inhibitor Treatment for Insomnia and ED
PDE5 inhibitors treat insomnia via cGMP-mediated pathways, avoiding CNS side effects and addiction risks associated with traditional sedatives.
- UT-A Selective Urea Transport Inhibitors for Refractory Edema
Nanomolar UT-A selective compounds resolve diuretic resistance by targeting urea transporters to treat refractory edema.
- D1R Agonist and ARB Combination for Long COVID Viral Reservoirs
Combining a D1R partial agonist with a BBB-crossing ARB targets cellular entry pathways to neutralize viral particles in infected tissues.
- Alpha-3 Glycine Receptor Agonists for Neuropathic Pain Relief
Alpha-3 glycine receptor agonists modulate spinal cord dorsal horn inhibitory transmission to reverse tactile allodynia, avoiding opiate-induced sedation.
- Combinatorial Pharmacotherapy for Neuro-Function Restoration
A combinatorial pharmacological composition merges multiple therapeutic agents to enhance neuro-restoration through synergistic multi-mechanism action.
- AKAP18δ-Phospholamban Inhibitors for Cardiac Signaling
Tertiary amine compounds interfere with AKAP18δ-phospholamban binding to regulate SERCA2 activity and treat reperfusion syndrome.
- Eupatilin Chromone Derivative Inhibits EMT Fibrosis
A eupatilin chromone derivative inhibits epithelial mesenchymal transition to suppress fibrosis progression.
- Multi-Component Medication for Nausea and Vertigo Relief
Combines antiemetics with analgesics to treat diverse symptoms.
- Ryanodine Receptor Inhibitors for T-Cell Disorders
Selective ryanodine receptor inhibitors block calcium efflux from type 1 and 3 receptors, reducing T cell activation while preserving normal immune function.
- HDAC and ACE Inhibitor Combination for Heart Failure
Phenylbutyrate reverses aberrant gene silencing while captopril stabilizes hemodynamics to treat heart failure.
- Chronic Pain Composition Merging SNRI and NSAID
Merges multiple analgesics into one composition to reduce administration complexity while preventing opioid dependence through antagonist integration.
- PDE7 Inhibitors for Addiction Treatment via Neurobiological Pathway Modulation
Phosphodiesterase 7 inhibitors target neurobiological pathways to reduce relapse rates in addiction treatment, addressing limited efficacy of current therapies.
- KNDy Neuron Inhibition for Vasomotor Symptom Treatment
Targeting kisspeptin neurons with receptor antagonists treats hot flashes without estrogen risks.
- Small Molecule Inhibitors Block Bacterial Toxin Translocation
Compounds stabilize toxin A subunits to prevent cellular entry.
- Modular PROTAC Design for Targeted Protein Degradation
Segmented bivalent ligands link targets to E3 ligases, resolving inefficiencies in degrader design.
- KP372-1 Redox-Cycling Agent for Selective Pancreatic Cancer Treatment
A redox-cycling agent induces cytotoxicity in cancer cells by creating a redox imbalance.
- ATM and Chk2 Inhibitor Combinations for HSV-1 Treatment
Combining ATM or Chk2 inhibitors with anti-herpetic agents reduces viral replication while minimizing drug resistance and side effects.
- Quinoline Derivative Inhibiting ESET/SETDB1 for Huntington's Disease
A quinoline derivative inhibits histone methyltransferase activity to block pathological protein modification.
- Noribogaine Migraine Treatment Dosing and Delivery
Narrow noribogaine dosing combined with direct bloodstream routes alleviates migraine severity while minimizing QT interval prolongation.
- Melanoma Treatment via DHODH and BRAF Inhibitor Synergy
Dual-target therapy merges BRAF and DHODH inhibitors to overcome resistance and side effects, achieving significant tumor regression.
- Mito-metformin Neuroprotection via Mitochondrial Targeting
Triphenylphosphonium-modified metformin accumulates in mitochondria to halt neurodegeneration instead of merely compensating for symptoms.
- D-cycloserine intermittent dosing for dementia tolerance
Periodic D-cycloserine dosing prevents rapid tolerance development while maintaining cognitive improvement and reducing side effects.